CVRx

CVRX

Medical - Devices · Healthcare

Price

$2.84

+0.00 (+0.00%)

Market Cap

$75.4M

Exchange

NASDAQ

Winston Score

Winston is serious

Below-average fundamentals — multiple weak pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Mixed

Growth

Good

Cash Flow

Weak

Stability

Weak

Valuation

Data not available

Track this stock — start free trial

Share count rising — dilution

+25.9% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 20.7M (2021) → 26.1M (2025)

Winston Score History

The full picture

CVRx makes a small medical device that is implanted in the body to treat heart failure. The device is called Barostim, and it works by sending gentle electrical signals to nerves near the neck to help the heart and blood vessels work better. It is sold to hospitals and heart specialists in the United States and parts of Europe.

The company earns money by selling the Barostim implant hardware and related components to medical centers that perform the procedure. CVRx is a small company with a market cap around $100 million, and Barostim holds a unique position as the only FDA-approved device of its kind for heart failure with this specific mechanism. However, the company is spending far more than it earns — its operating margin is deeply negative — meaning the main risk is whether it can grow sales fast enough to reach profitability before needing to raise more cash.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+15.6% YoY

YoY Growth Rate

Steady revenue growth

EPS Growth

+7.0% YoY

YoY Growth Rate

Slow EPS growth

R&D Spend

$11M/ year

→ Flat (+0% vs prior year)

19.7% of revenue

In line with sector average (18%)

Steady R&D investment year-over-year

Insider Activity

30.9%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~9 months

$65M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

CVRx has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

87.4%

Premium pricing power — 87.4% gross margin

Profit after running costs

Operating Margin

-82.9%

Losing money on operations — -82.9%

Return on the money invested

ROCE

-61.6%

Weak — -61.6% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+12.0%

Steady sales growth (+12.0% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-87.2%

Burning cash (-87.2%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

2.96

Heavy debt load (2.96)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial